NIAID describes challenges, prospects for an HIV vaccine

August 28, 2008

WHAT: Events of the past year in HIV vaccine research have led some to question whether an effective HIV vaccine will ever be developed. In the August 28 edition of the New England Journal of Medicine, officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine the extraordinarily challenging properties of the virus that have made a vaccine elusive and outline the scientific questions that, if answered, could lead to an effective HIV vaccine.

In recent years, the most extensively studied HIV vaccines have aimed to mobilize immune cells called T cells, write Anthony S. Fauci, M.D., NIAID director, and Margaret I. Johnston, Ph.D., director of the Vaccine Research Program in NIAID's Division of AIDS. T-cell vaccines are not expected to prevent HIV infection. Rather, they could potentially reduce the level of virus (but not eliminate it) following infection, limit the number of immune cells that HIV destroys, and thus delay the progression to AIDS. There is no evidence yet that T-cell HIV vaccines work in humans, however. If the vaccines ultimately do, their effectiveness may vary greatly depending on the genetic make-up of each individual, given that T-cell immunity is dependent on genetic factors. Furthermore, because the virus would persist in the blood of vaccinated individuals, T-cell vaccines would likely generate only transient "herd immunity"--that is, population-wide protection from disease conferred by vaccination of a percentage of the community.

In response to the failure last September of a T-cell vaccine for which many people had high hopes, the HIV vaccine field has undergone a self-reexamination and has determined that the balance between fundamental discovery research and product development should shift toward discovery. In particular, future research must intensify the study of broadly neutralizing antibodies to HIV, why most HIV-infected people do not make them, and the design of novel strategies to induce them with a vaccine. Also, studying the earliest stages of HIV infection may shed light on ways to manipulate innate and mucosal immune responses to widen the window of opportunity for viral eradication, to prevent the virus from advancing to gut-associated lymphoid tissue, or both.

The authors conclude with cautious optimism that an effective HIV vaccine will be developed, but will depend on the significant growth of scientific understanding of HIV disease and human responses to the virus.

NIH/National Institute of Allergy and Infectious Diseases

---

---

	Immunology and the Quest for an HIV Vaccine: A New Perspective by Dr. Omar Bagasra (Author) How many human immune systems are there? How old are they? Why is there no AIDS vaccine? Is a new approach needed? Why is public opinion growing skeptical of the scientific community after three decades of public awareness about HIV/AIDS? Consider answers to these puzzling questions. Learn from the decades of experience of two senior scholars: Dr. Omar Bagasra (an eminent molecular biologist, immunologist, and retrovirologist) and Dr. Donald Gene Pace (a highly published writer who examines public health policy). Explore intriguing new possibilities about human immunity, and the development of an effective AIDS vaccine. Read Immunology and the Quest for an HIV Vaccine. Benefit from an informed synthesis backed by a wealth of peer-reviewed scientific references. Review basic concepts of...
	HIV And Molecular Immunity: Prospects for the AIDS Vaccine by Omar Bagasra (Author) How old is the AIDS virus (HIV-1) and where did it come from? Is it the result of a recombinant event in simian immunodeficiency viruses (SIVs)? Why do SIVs naturally occur in a variety of nonhuman African primates without inducing AIDS in their natural hosts? HIV-1 has devastated human society, although chimpanzees carry an SIV that is genetically almost identical to HIV-1 but causes no known illness in these great apes. How are Chimpanzees immune to HIV-1? Can humans acquire this immunity? Why do most newborns infected with HIV-1 in utero or during birth become long-term non-progressors while 20% rapidly develop AIDS and die in less than a year? Why are some adults asymptomatic for over 10 years after infection? Dr. Omar Bagasra, an eminent molecular biologist, immunologist, and...
	Expanding Access to Investigational Therapies for HIV Infection and AIDS by Roundtable for the Development of Drugs and Vaccines Against AIDS (Author), Institute of Medicine (Author) The call for a "parallel track" for AIDS drug development-a proposal that would allow the early distribution of AIDS drugs to large numbers of patients in parallel with the conventional clinical trials that assess the drugs' safety and efficacy-has sparked controversy within the scientific community. Questions have arisen about the risks to patients of such a plan, about its potential effect on the successful completion of standard controlled trials, and about whether the parallel track will generate useful data. Larger questions have also been raised about whether the parallel track heralds fundamental changes in the philosophy underlying drug regulation in the United States, about the costs and financing of investigational therapies and associated medical costs, and about the role of...
	AIDS Vaccine Research by WonG-Staal/Gall (Author) This reference describes the latest advances in the development and design of an HIV preventive vaccine-detailing the pathogenesis and genetic variability of HIV infection for the construction of molecular and therapeutic strategies to reduce the progression and transmission of AIDS. With contributions by universally recognized authorities in the field, AIDS Vaccine Research discusses § major obstacles in the identification of a preventive vaccine § the role of innate immunity in management of HIV infection § the impact of highly active antiretroviral therapy (HAART) on AIDS research § the creation of an effective mucosal DNA vaccine § the effect of the AIDS epidemic on developing countries Offering nearly 2000 contemporary references to facilitate further study, AIDS Vaccine...
	The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive HIV Vaccine (Medical Ethics) by Christine Grady (Author) "The book is a balanced and comprehensive treatment of an important social issue. It is accessible to the general reader and belongs in public as well as academic libraries." —Religious Studies Review"Painstaking analysis of the knotty ethical problems involved in human-subjects research, and a well-thought-out proposal for a community approach to conducting field trials for an HIV vaccine.... Highly recommended for medical ethicists and anyone concerned about the AIDS epidemic and how HIV research is conducted." —Kirkus Reviews"... a carefully reasoned account of how research for and trial of a preventive vaccine differ from the methods used to discover a therapy." —Booklist"I highly recommend reading this book which I would attest to be a thrilling, ethically challenging,...
	Ethical Issues in HIV Vaccine Trials. by Thomas A. KERNS (Author)
	AIDS: Anti HIV Agents, Therapies And Vaccines (Annals of the New York Academy of Sciences) by Vassil St. Georgiev (Author), John J. McGowan (Editor)
	AIDS Vaccines, HIV Receptors, and AIDS Research by Lawrence B. Kendow (Author) Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a set of symptoms and infections resulting from the damage to the human immune system caused by the human immunodeficiency virus (HIV). This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to opportunistic infections and tumours. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, pre-seminal fluid, and breast milk. This transmission can involve anal, vaginal or oral sex, blood transfusion, contaminated hypodermic needles, exchange between mother and baby during pregnancy, childbirth, or breastfeeding, or other exposure to one of the above...
	The First Decade of Safe and Effective HIV Vaccines by Jeremiah O. A. Abalaka (Author) Since 1984, the world has been spending, on the average, over $700 million annually in a futile effort at developing safe and effective HIV vaccines. During this period, over 25 million people have perished from the HIV/AIDS scourge, 90 per cent of them in the poor developing countries of sub-Saharan Africa. The socio-economic wreck caused by the HIV/AIDS pandemic is mind-boggling. The years of wayward search for safe and effective HIV vaccines since 1984 should have shown the world that the recipe for HIV vaccines that they have been following religiously without success should be appraised. That has not been done up till today. Instead, the entire world has persisted with the unscientific, unreasonable, bizarre, and ridiculous dogmas and established knowledge. Globally, the world has...
	HIV/Vaccine Needs - Procs of the Intl Seminar on Planetary Emergencies, 24th Session by Richard C. Ragaini (Author), Ragaini Richard (Author) This exploration of HIV/AIDS vaccine needs is taken from the 24th Session of the International Seminar on Nuclear War and Planetary Emergencies. Topics covered include: biotechnology; neuropathologies; development; sustainability; energy; water; and more.